Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA mutant |
Therapy | Perifosine |
Indication/Tumor Type | endometrial cancer |
Response Type | not predictive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mutant | endometrial cancer | not predictive | Perifosine | Phase II | Actionable | In a Phase II trial , Perifosine (KRX-0401) treatment was well-tolerated, resulted in stable disease as best response in patients with recurrent endometrial cancer, no significant difference in disease control rate (47.1%, 8/17 vs 14.3%, 1/7, p=0.19), median progression-free survival (HR=1.71, p=0.30), or median overall survival (HR=0.92, p=0.88) was identified between PIK3CA wild-type and PIK3CA mutant patients (PMID: 28864978). | 28864978 |
PubMed Id | Reference Title | Details |
---|---|---|
(28864978) | Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations. | Full reference... |